메뉴 건너뛰기




Volumn 105, Issue SUPPL. 2, 2011, Pages

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics

Author keywords

Aerosolized antibiotics; Aminoglycosides; Aztreonam lysine for inhalation solution (AZLI); Cystic fibrosis; FEV 1; Fluoroquinolones; Minimum inhibitory concentration (MIC); Polymyxins; Pseudomonas aeruginosa; Tobramycin inhalation solution (TIS)

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ARIKACE; AZTREONAM LYSINE; BRAMITOB; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; LEVOFLOXACIN; PLACEBO; PODHALER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG;

EID: 84855267772     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/S0954-6111(11)70021-X     Document Type: Article
Times cited : (27)

References (69)
  • 3
    • 0038102859 scopus 로고    scopus 로고
    • Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
    • DOI 10.1016/S1569-1993(02)00141-8, PII S1569199302001418
    • TW Lee, KG Brownlee, SP Conway, M Denton, JM Littlewood Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients J Cyst Fibros 2 2003 29 34 (Pubitemid 36857407)
    • (2003) Journal of Cystic Fibrosis , vol.2 , Issue.1 , pp. 29-34
    • Lee, T.W.R.1    Brownlee, K.G.2    Conway, S.P.3    Denton, M.4    Littlewood, J.M.5
  • 4
    • 0142105983 scopus 로고    scopus 로고
    • Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management
    • M Rosenfeld, BW Ramsey, RL Gibson Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management Curr Opin Pulm Med 9 2003 492 497 (Pubitemid 37268213)
    • (2003) Current Opinion in Pulmonary Medicine , vol.9 , Issue.6 , pp. 492-497
    • Rosenfeld, M.1    Ramsey, B.W.2    Gibson, R.L.3
  • 6
    • 0036320272 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    • DOI 10.1002/ppul.10127
    • J Emerson, M Rosenfeld, S McNamara, B Ramsey, RL Gibson Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pediatr Pulmonol 34 2002 91 100 (Pubitemid 34809519)
    • (2002) Pediatric Pulmonology , vol.34 , Issue.2 , pp. 91-100
    • Emerson, J.1    Rosenfeld, M.2    McNamara, S.3    Ramsey, B.4    Gibson, R.L.5
  • 7
    • 0029177535 scopus 로고
    • Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis
    • A Pamukcu, A Bush, R Buchdahl Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis Pediatr Pulmonol 19 1995 10 15
    • (1995) Pediatr Pulmonol , vol.19 , pp. 10-15
    • Pamukcu, A.1    Bush, A.2    Buchdahl, R.3
  • 9
    • 0026831341 scopus 로고
    • Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
    • RL Henry, CM Mellis, L Petrovic Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis Pediatr Pulmonol 12 1992 158 161
    • (1992) Pediatr Pulmonol , vol.12 , pp. 158-161
    • Henry, R.L.1    Mellis, C.M.2    Petrovic, L.3
  • 10
    • 0031661390 scopus 로고    scopus 로고
    • 1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis
    • 1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis Thorax 53 1998 732 737 (Pubitemid 28408712)
    • (1998) Thorax , vol.53 , Issue.9 , pp. 732-737
    • Ballmann, M.1    Rabsch, P.2    Von Der Hardt, H.3
  • 12
    • 66849126372 scopus 로고    scopus 로고
    • Bugs, biofilms, and resistance in cystic fibrosis
    • JC Davies Bugs, biofilms, and resistance in cystic fibrosis Respir Care 54 2009 628 638
    • (2009) Respir Care , vol.54 , pp. 628-638
    • Davies, J.C.1
  • 14
    • 77953635880 scopus 로고    scopus 로고
    • Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis
    • EC Dasenbrook, W Checkley, CA Merlo, MW Konstan, N Lechtzin, MP Boyle Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis JAMA 303 2010 2386 2392
    • (2010) JAMA , vol.303 , pp. 2386-2392
    • Dasenbrook, E.C.1    Checkley, W.2    Merlo, C.A.3    Konstan, M.W.4    Lechtzin, N.5    Boyle, M.P.6
  • 15
    • 67249099362 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients
    • T Bjarnsholt, PO Jensen, MJ Fiandaca et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients Pediatr Pulmonol 44 2009 547 558
    • (2009) Pediatr Pulmonol , vol.44 , pp. 547-558
    • Bjarnsholt, T.1    Jensen, P.O.2    Fiandaca, M.J.3
  • 16
    • 77950914953 scopus 로고    scopus 로고
    • Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial
    • F Ratjen, A Munck, P Kho, G Angyalosi Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial Thorax 65 2010 286 291
    • (2010) Thorax , vol.65 , pp. 286-291
    • Ratjen, F.1    Munck, A.2    Kho, P.3    Angyalosi, G.4
  • 17
    • 59649123905 scopus 로고    scopus 로고
    • Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis
    • TA Douglas, S Brennan, S Gard et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis Eur Respir J 33 2009 305 311
    • (2009) Eur Respir J , vol.33 , pp. 305-311
    • Douglas, T.A.1    Brennan, S.2    Gard, S.3
  • 18
    • 50849131275 scopus 로고    scopus 로고
    • Shifting patterns of inhaled antibiotic use in cystic fibrosis
    • SM Moskowitz, SJ Silva, N Mayer-Hamblett et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis Pediatr Pulmonol 43 2008 874 881
    • (2008) Pediatr Pulmonol , vol.43 , pp. 874-881
    • Moskowitz, S.M.1    Silva, S.J.2    Mayer-Hamblett, N.3
  • 19
    • 79953284775 scopus 로고    scopus 로고
    • Inhaled antibiotics for long-term therapy in cystic fibrosis
    • G Ryan, M Singh, K Dwan Inhaled antibiotics for long-term therapy in cystic fibrosis Cochrane Database Syst Rev 2011 CD001021
    • (2011) Cochrane Database Syst Rev , pp. 001021
    • Ryan, G.1    Singh, M.2    Dwan, K.3
  • 20
    • 0002101312 scopus 로고
    • Celiac syndrome; Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; Observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol
    • PEA di Sant' Agnese, DH Andersen Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol Am J Dis Child 72 1946 17 61
    • (1946) Am J Dis Child , vol.72 , pp. 17-61
    • Di Sant'Agnese, P.E.A.1    Andersen, D.H.2
  • 21
    • 13244279718 scopus 로고    scopus 로고
    • Nebulized antibiotic therapy: The evidence
    • DOI 10.1191/1479972305cd045rs
    • SP Conway Nebulized antibiotic therapy: the evidence Chronic Respir Dis 2 2005 35 41 (Pubitemid 40193822)
    • (2005) Chronic Respiratory Disease , vol.2 , Issue.1 , pp. 35-41
    • Conway, S.P.1
  • 22
    • 0022353251 scopus 로고
    • Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
    • PM Mendelman, AL Smith, J Levy, A Weber, B Ramsey, RL Davis Aminoglycoside penetration, inactivation, and efficiency in cystic fibrosis sputum Am Rev Respir Dis 132 1985 761 765 (Pubitemid 16247735)
    • (1985) American Review of Respiratory Disease , vol.132 , Issue.4 , pp. 761-765
    • Mendelman, P.M.1    Smith, A.L.2    Levy, J.3
  • 24
    • 0024790626 scopus 로고
    • Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
    • AL Smith, BW Ramsey, DL Hedges et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis Pediatr Pulmonol 7 1989 265 271
    • (1989) Pediatr Pulmonol , vol.7 , pp. 265-271
    • Smith, A.L.1    Ramsey, B.W.2    Hedges, D.L.3
  • 26
    • 0030898932 scopus 로고    scopus 로고
    • Effect of nebulizer type and antibiotic concentration on device performance
    • DOI 10.1002/(SICI)1099-0496(199704)23:4<249::AID-PPUL2>3.0.CO;2-H
    • A Weber, G Morlin, M Cohen, J Williams-Warren, B Ramsey, A Smith Effect of nebulizer type and antibiotic concentration on device performance Pediatr Pulmonol 23 1997 249 260 (Pubitemid 27185033)
    • (1997) Pediatric Pulmonology , vol.23 , Issue.4 , pp. 249-260
    • Weber, A.1    Morlin, G.2    Cohen, M.3    Williams-Warren, J.4    Ramsey, B.5    Smith, A.6
  • 27
    • 0036304163 scopus 로고    scopus 로고
    • Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    • DOI 10.1378/chest.122.1.219
    • DE Geller, WH Pitlick, PA Nardella, WG Tracewell, BW Ramsey Pharmacokinetics and bioavailability of aerosolized tobramycin (TOBI®) in cystic fibrosis Chest 122 2002 219 226 (Pubitemid 34754166)
    • (2002) Chest , vol.122 , Issue.1 , pp. 219-226
    • Geller, D.E.1    Pitlick, W.H.2    Nardella, P.A.3    Tracewell, W.G.4    Ramsey, B.W.5
  • 28
    • 0030999183 scopus 로고    scopus 로고
    • A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
    • J Eisenberg, M Pepe, J Williams-Warren et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems Chest 111 1997 955 962 (Pubitemid 27171467)
    • (1997) Chest , vol.111 , Issue.4 , pp. 955-962
    • Eisenberg, J.1    Pepe, M.2    Williams-Warren, J.3    Vasiliev, M.4    Bruce Montgomery, A.5    Smith, A.L.6    Ramsey, B.W.7
  • 29
    • 84873076258 scopus 로고    scopus 로고
    • Novartis Pharmaceuticals Corporation East Hanover, NJ (accessed October 3, 2011).
    • TOBI® (tobramycin inhalation solution) Prescribing Information 2009 Novartis Pharmaceuticals Corporation East Hanover, NJ Available at: www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf (accessed October 3, 2011).
    • (2009) TOBI® (Tobramycin Inhalation Solution) Prescribing Information
  • 31
    • 0036157901 scopus 로고    scopus 로고
    • Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    • DOI 10.1378/chest.121.1.55
    • RB Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 121 2002 55 63 (Pubitemid 34114228)
    • (2002) Chest , vol.121 , Issue.1 , pp. 55-63
    • Moss, R.B.1
  • 32
    • 0034834836 scopus 로고    scopus 로고
    • Administration of aerosolized antibiotics in cystic fibrosis patients
    • RB Moss Administration of aerosolized antibiotics in cystic fibrosis patients Chest 120 3 Suppl 2001 107S 113S (Pubitemid 32881572)
    • (2001) Chest , vol.120 , Issue.SUPPL.
    • Moss, R.B.1
  • 34
    • 84855266619 scopus 로고    scopus 로고
    • Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
    • DE Geller, S Madge Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis Respir Med 105 Suppl 2 2011 S24 S31
    • (2011) Respir Med , vol.105 , Issue.SUPPL. 2
    • Geller, D.E.1    Madge, S.2
  • 35
    • 34249945743 scopus 로고    scopus 로고
    • A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo-controlled, multicenter study
    • DOI 10.2165/00148581-200709001-00004
    • A Chuchalin, E Csiszér, K Gyurkovics et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Paediatr Drugs 9 Suppl 1 2007 21 31 (Pubitemid 46879111)
    • (2007) Pediatric Drugs , vol.9 , Issue.SUPPL. 1 , pp. 21-31
    • Chuchalin, A.1    Csiszer, E.2    Gyurkovics, K.3    Bartnicka, M.T.4    Sands, D.5    Kapranov, N.6    Varoli, G.7    Preti, P.A.M.8    Mazurek, H.9
  • 37
    • 77956566583 scopus 로고    scopus 로고
    • Gilead Sciences, Inc. Foster City, CA (accessed October 29, 2011).
    • Cayston® (aztreonam for inhalation solution). Prescribing Information 2010 Gilead Sciences, Inc. Foster City, CA Available at: https://www.cayston. com/assets/media/pdfs/CAYSTON-full-prescribing-information.pdf (accessed October 29, 2011).
    • (2010) Cayston® (Aztreonam for Inhalation Solution). Prescribing Information
  • 38
    • 84873066911 scopus 로고    scopus 로고
    • accessed October 29, 2011
    • European Medicines Agency Cayston Available at: http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000996/human-med-000686. jsp&mid=WC0b01ac058001d124 (accessed October 29, 2011).
    • Cayston
    • Medicines Agency, E.1
  • 39
    • 33745686502 scopus 로고    scopus 로고
    • Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    • RL Gibson, GZ Retch-Bogart, C Oermann et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Pediatr Pulmonol 41 2006 656 665
    • (2006) Pediatr Pulmonol , vol.41 , pp. 656-665
    • Gibson, R.L.1    Retch-Bogart, G.Z.2    Oermann, C.3
  • 40
    • 38349058630 scopus 로고    scopus 로고
    • A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    • GZ Retsch-Bogart, JL Burns, KL Otto et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection Pediatr Pulmonol 43 2008 47 58
    • (2008) Pediatr Pulmonol , vol.43 , pp. 47-58
    • Retsch-Bogart, G.Z.1    Burns, J.L.2    Otto, K.L.3
  • 41
    • 65949124667 scopus 로고    scopus 로고
    • Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
    • GZ Retsch-Bogart, AL Quittner, RL Gibson et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis Chest 135 2009 1223 1232
    • (2009) Chest , vol.135 , pp. 1223-1232
    • Retsch-Bogart, G.Z.1    Quittner, A.L.2    Gibson, R.L.3
  • 43
    • 78449294500 scopus 로고    scopus 로고
    • An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis
    • CM Oermann, GZ Retsch-Bogart, AL Quittner et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis Pediatr Pulmonol 45 2010 1121 1134
    • (2010) Pediatr Pulmonol , vol.45 , pp. 1121-1134
    • Oermann, C.M.1    Retsch-Bogart, G.Z.2    Quittner, A.L.3
  • 45
    • 79958295843 scopus 로고    scopus 로고
    • Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
    • CE Wainwright, AL Quittner, DE Geller et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa J Cyst Fibros 10 2011 234 242
    • (2011) J Cyst Fibros , vol.10 , pp. 234-242
    • Wainwright, C.E.1    Quittner, A.L.2    Geller, D.E.3
  • 46
    • 55549102981 scopus 로고    scopus 로고
    • Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience
    • CR Hansen, T Pressler, N Høiby Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience J Cyst Fibros 7 2008 523 530
    • (2008) J Cyst Fibros , vol.7 , pp. 523-530
    • Hansen, C.R.1    Pressler, T.2    Høiby, N.3
  • 47
    • 0023265976 scopus 로고
    • Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
    • T Jensen, SS Pedersen, S Garne, C Heilmann, N Høiby, C Koch Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Antimicrob Chemother 19 1987 831 838 (Pubitemid 17092071)
    • (1987) Journal of Antimicrobial Chemotherapy , vol.19 , Issue.6 , pp. 831-838
    • Jensen, T.1    Pedersen, S.S.2    Garne, S.3
  • 48
    • 0036736583 scopus 로고    scopus 로고
    • A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    • ME Hodson, CG Gallagher, JR Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 20 2002 658 664
    • (2002) Eur Respir J , vol.20 , pp. 658-664
    • Hodson, M.E.1    Gallagher, C.G.2    Govan, J.R.3
  • 50
    • 69549135253 scopus 로고    scopus 로고
    • Inhaled medication and inhalation devices for lung disease in patients with CF: A European consensus
    • H Heijerman, E Westerman, S Conway, D Touw, G Döring, consensus working group Inhaled medication and inhalation devices for lung disease in patients with CF: a European consensus J Cyst Fibros 8 2009 295 315
    • (2009) J Cyst Fibros , vol.8 , pp. 295-315
    • Heijerman, H.1    Westerman, E.2    Conway, S.3    Touw, D.4    Döring, G.5    Working Group, C.6
  • 52
    • 36548999921 scopus 로고    scopus 로고
    • Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome
    • KS McCoy Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome N Engl J Med 357 2008 2310 2311
    • (2008) N Engl J Med , vol.357 , pp. 2310-2311
    • McCoy, K.S.1
  • 54
    • 84885072715 scopus 로고    scopus 로고
    • accessed October 29, 2011
    • European Medicines Agency Colobreathe Available at: http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/smops/ Positive/human-smop-000270.jsp&mid=WC0b01ac058001d127&jsenabled=true (accessed October 29, 2011).
    • Colobreathe
    • Medicines Agency, E.1
  • 55
    • 79961039597 scopus 로고    scopus 로고
    • Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology
    • DE Geller, J Weers, S Heuerding Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology J Aerosol Med Pulm Drug Deliv 24 2011 175 182
    • (2011) J Aerosol Med Pulm Drug Deliv , vol.24 , pp. 175-182
    • Geller, D.E.1    Weers, J.2    Heuerding, S.3
  • 56
    • 34247193128 scopus 로고    scopus 로고
    • Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
    • DOI 10.1002/ppul.20594
    • DE Geller, M Konstan, J Smith, S Noonberg, C Conrad A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol 42 2007 307 313 (Pubitemid 46608898)
    • (2007) Pediatric Pulmonology , vol.42 , Issue.4 , pp. 307-313
    • Geller, D.E.1    Konstan, M.W.2    Smith, J.3    Moonberg, S.B.4    Conrad, C.5
  • 58
    • 78651412529 scopus 로고    scopus 로고
    • Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    • MW Konstan, PA Flume, M Kappler et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J Cyst Fibros 10 2011 54 61
    • (2011) J Cyst Fibros , vol.10 , pp. 54-61
    • Konstan, M.W.1    Flume, P.A.2    Kappler, M.3
  • 60
    • 84873063990 scopus 로고    scopus 로고
    • Insmed Incorporated Monmouth Junction, NJ (accessed October 29, 2011).
    • Arikace® (inhaled liposomal amikacin) 2011 Insmed Incorporated Monmouth Junction, NJ Available at: http://www.insmed.com/arikace.phpp1 (accessed October 29, 2011).
    • (2011) Arikace® (Inhaled Liposomal Amikacin)
  • 62
    • 66949178892 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
    • Abstract 102.
    • L Dupont, P Minic, S Fustik et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 102.
    • (2008) J Cyst Fibros , vol.7 , Issue.SUPPL. 2 , pp. 26
    • Dupont, L.1    Minic, P.2    Fustik, S.3
  • 63
    • 84873073687 scopus 로고    scopus 로고
    • A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
    • Abstract 217.
    • P Minic, S Fustik, E Solyom et al. A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Cyst Fibros 10 Suppl 1 2011 S55 Abstract 217.
    • (2011) J Cyst Fibros , vol.10 , Issue.SUPPL. 1 , pp. 55
    • Minic, P.1    Fustik, S.2    Solyom, E.3
  • 64
    • 66949153801 scopus 로고    scopus 로고
    • Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder
    • Abstract 103.
    • H Stass, S Baumann-Noss, H Delesen et al. Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 103.
    • (2008) J Cyst Fibros , vol.7 , Issue.SUPPL. 2 , pp. 26
    • Stass, H.1    Baumann-Noss, S.2    Delesen, H.3
  • 65
    • 66949159248 scopus 로고    scopus 로고
    • The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization
    • Abstract 401.
    • P Bruinenberg, B Otulana, J Blanchard et al. The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization Pediatr Pulmonol 43 Suppl 31 2008 344 Abstract 401.
    • (2008) Pediatr Pulmonol , vol.43 , Issue.SUPPL. 31 , pp. 344
    • Bruinenberg, P.1    Otulana, B.2    Blanchard, J.3
  • 66
    • 73849128431 scopus 로고    scopus 로고
    • In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis
    • P King, O Lomovskaya, DC Griffith, JL Burns, MN Dudley In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis Antimicrob Agents Chemother 54 2010 143 148
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 143-148
    • King, P.1    Lomovskaya, O.2    Griffith, D.C.3    Burns, J.L.4    Dudley, M.N.5
  • 67
    • 73749084328 scopus 로고    scopus 로고
    • Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients
    • P King, DM Citron, DC Griffith, O Lomovskaya, MN Dudley Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients Diagn Microbiol Infect Dis 66 2010 181 186
    • (2010) Diagn Microbiol Infect Dis , vol.66 , pp. 181-186
    • King, P.1    Citron, D.M.2    Griffith, D.C.3    Lomovskaya, O.4    Dudley, M.N.5
  • 68
    • 79957942626 scopus 로고    scopus 로고
    • Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
    • Mpex204 Study Group
    • DE Geller, PA Flume, D Staab, R Fischer, JS Loutit, DJ Conrad, Mpex204 Study Group Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 2011 1510 1516
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 1510-1516
    • Geller, D.E.1    Flume, P.A.2    Staab, D.3    Fischer, R.4    Loutit, J.S.5    Conrad, D.J.6
  • 69
    • 84855292491 scopus 로고    scopus 로고
    • Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection
    • in press
    • BC Trapnell, SA McColley, DG Kissner et al. Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection Am J Respir Crit Care Med 2011 (in press).
    • (2011) Am J Respir Crit Care Med
    • Trapnell, B.C.1    McColley, S.A.2    Kissner, D.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.